Analyst Consensus ?
ConsensusHold32 ratings
Bullish1443.8%
Neutral1856.2%
Bearish00.0%
Zoetis Inc. · ZTS · FY2024 Q4 · Calendar Q1 2025
Zoetis: Durable Franchise Growth, but Competition Is Rising
The call provides evidence for a constructive one-year growth case: management highlighted expansion in parasiticides, osteoarthritis-pain biologics, alternative channels and the product pipeline. That case remains conditional because competition, pricing and volume mix, foreign exchange, regulatory scrutiny and the durability of margin improvement could offset franchise momentum.
Reported Before market openNYSEHealthcare
$33.48B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $1.37
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $2.32B
Revenue surprise
—
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-5.1%
Event window
SPY move
+1.1%
Same window
Abnormal move
-6.2%
Stock minus SPY
Volume
4.7×
Versus trailing sessions
Subsequent drift
-2.2%
Up to 20 sessions
ZTSSPY benchmark
Ask FN2 about ZTS FY2024 Q4
Transcript, numbers and history already loaded
What drove ZTS's -5.1% move after FY2024 Q4 earnings?What changed in ZTS's guidance and outlook in FY2024 Q4?Give me the bull and bear case for ZTS after FY2024 Q4 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior analysis, the outlook shifted from a raised FY2024 revenue view to a maintained 2025 framework. Management emphasized 2025 organic growth, continued expansion of Simparica, Librela and Solensia, and portfolio focus after the MFA divestiture.
Guidance delta
Management maintained its 2025 outlook, targeting 6–8% organic revenue growth and 2–4% adjusted net-income growth.
Key takeaways
- Management described 11% operational revenue growth in FY2024, led by companion-animal franchises.
- Simparica Trio, Librela and Solensia were identified as major growth drivers, alongside pipeline opportunities.
- The 2025 outlook calls for 6–8% organic revenue growth and 2–4% adjusted net-income growth.
- The investment case is supported by franchise expansion, but faces competition, pricing, foreign-exchange and regulatory risks.
Management priorities
- Expand Simparica, Librela, Solensia and other key franchises through omni-channel distribution.
- Advance pipeline products and long-acting formulations in chronic kidney disease, oncology and cardiology.
- Use field-force education and veterinary outreach to support adoption and market share.
- Focus the portfolio on higher-growth, higher-value lines following the MFA divestiture.
Follow ZTS with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$81.03Current
$74Low
$135.12Average
$254High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 24, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Jefferies | Hold | Buy | Downgrade | Oct 20, 2026 |
| TD Cowen | Buy | Buy | Maintain | Aug 25, 2026 |
| Stifel | Hold | Hold | Maintain | Aug 20, 2026 |
| Citigroup | Buy | Buy | Maintain | Aug 11, 2026 |
| BNP Paribas | Outperform | Outperform | Maintain | Aug 11, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Aug 10, 2026 |
| UBS | Neutral | Neutral | Maintain | Aug 7, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Aug 7, 2026 |
| William Blair | Market Perform | Outperform | Downgrade | Aug 6, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Jul 22, 2026 |
| HSBC | Buy | Buy | Maintain | Jul 6, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Jul 1, 2026 |
| Argus Research | Hold | Buy | Downgrade | May 27, 2026 |
| B of A Securities | Neutral | Neutral | Maintain | Feb 13, 2026 |
| BTIG | Buy | Buy | Maintain | Dec 3, 2025 |
| Leerink Partners | Market Perform | Outperform | Downgrade | Jul 17, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | May 6, 2024 |
| Atlantic Equities | Overweight | Overweight | Maintain | Jun 14, 2023 |
| Credit Suisse | Outperform | Outperform | Maintain | Aug 9, 2021 |
| Raymond James | Market Perform | Outperform | Downgrade | Jul 16, 2021 |
| Truist Securities | Hold | Hold | Maintain | May 10, 2021 |
| Gabelli & Co. | Hold | Buy | Downgrade | Aug 12, 2020 |
| CFRA | Strong Buy | Buy | Upgrade | Feb 13, 2020 |
| SunTrust Robinson Humphrey | Hold | Hold | Maintain | Aug 13, 2019 |
| Stifel Nicolaus | Buy | Buy | Maintain | Jul 22, 2019 |
| Bank of America | Neutral | Buy | Downgrade | Jul 1, 2019 |
| BMO Capital | Market Perform | Market Perform | Maintain | May 9, 2019 |
| Argus | Buy | Buy | Maintain | Aug 14, 2018 |
| Deutsche Bank | Hold | Hold | Maintain | Feb 16, 2018 |
| Cowen & Co. | Outperform | Market Perform | Upgrade | Dec 15, 2016 |
| Hilliard Lyons | Neutral | Long Term Buy | Downgrade | Nov 13, 2014 |
| Edward Jones | Hold | Buy | Downgrade | Nov 12, 2014 |
Named analyst price targets
Upside is calculated against the persisted current price $81.03. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Jefferies | Keith Devas | $83 | $79.59 | +2.4% | Oct 20, 2026 |
| Goldman Sachs | Analyst unavailable | $74 | $78.42 | -8.7% | Oct 16, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $94 | $77.17 | +16.0% | Aug 25, 2026 |
| Stifel Nicolaus | Jonathan Block | $80 | $76.68 | -1.3% | Aug 20, 2026 |
| Morgan Stanley | Analyst unavailable | $85 | $75.3 | +4.9% | Aug 7, 2026 |
| UBS | Analyst unavailable | $85 | $76.52 | +4.9% | Jul 27, 2026 |
| Morgan Stanley | Analyst unavailable | $99 | $75.5 | +22.2% | Jul 22, 2026 |
| HSBC | Analyst unavailable | $95 | $74.63 | +17.2% | Jul 6, 2026 |
| Barclays | Analyst unavailable | $85 | $71.91 | +4.9% | Jul 1, 2026 |
| Stifel Nicolaus | Analyst unavailable | $85 | $77.82 | +4.9% | Jun 26, 2026 |
| Stifel Nicolaus | Analyst unavailable | $95 | $80.06 | +17.2% | May 22, 2026 |
| Morgan Stanley | Erin Wright | $115 | $76.06 | +41.9% | May 15, 2026 |
| UBS | Analyst unavailable | $99 | $83.27 | +22.2% | May 8, 2026 |
| Stifel Nicolaus | Analyst unavailable | $105 | $87.31 | +29.6% | May 8, 2026 |
| UBS | Analyst unavailable | $130 | $116.71 | +60.4% | Apr 28, 2026 |
| BTIG | Mark Massaro | $160 | $128.95 | +97.5% | Feb 26, 2026 |
| UBS | Analyst unavailable | $136 | $122.75 | +67.8% | Jan 29, 2026 |
| Piper Sandler | David Westenberg | $135 | $125.08 | +66.6% | Jan 22, 2026 |
| Morgan Stanley | Analyst unavailable | $160 | $124.54 | +97.5% | Dec 18, 2025 |
| HSBC | Analyst unavailable | $140 | $115.75 | +72.8% | Dec 10, 2025 |
| Barclays | Analyst unavailable | $136 | $118.16 | +67.8% | Dec 8, 2025 |
| Stifel Nicolaus | Analyst unavailable | $140 | $125.5 | +72.8% | Nov 4, 2025 |
| UBS | Analyst unavailable | $158 | $144.9 | +95.0% | Oct 20, 2025 |
| Piper Sandler | David Westenberg | $215 | $148.86 | +165.3% | Aug 11, 2025 |
| Stifel Nicolaus | Jonathan Block | $160 | $161.67 | +97.5% | Jun 17, 2025 |
| UBS | Andrea Alfonso | $170 | $149.87 | +109.8% | May 7, 2025 |
| Stifel Nicolaus | Jonathan Block | $165 | $150.83 | +103.6% | Apr 14, 2025 |
| Morgan Stanley | Erin Wright | $243 | $172.24 | +199.9% | Feb 4, 2025 |
| Barclays | Balaji Prasad | $242 | $185.29 | +198.7% | Aug 7, 2024 |
| Stifel Nicolaus | Jonathan Block | $200 | $176.31 | +146.8% | Aug 5, 2024 |
| Piper Sandler | David Westenberg | $195 | $149.77 | +140.7% | Apr 16, 2024 |
| Stifel Nicolaus | Jonathan Block | $195 | $167.02 | +140.7% | Apr 2, 2024 |
| Morgan Stanley | Analyst unavailable | $248 | $150.25 | +206.1% | Nov 15, 2022 |
| Jefferies | David Steinberg | $254 | $191.32 | +213.5% | Feb 21, 2022 |
| Argus Research | Jasper Hellweg | $225 | $203.86 | +177.7% | Aug 25, 2021 |
| Credit Suisse | Katie Tryhane | $230 | $199.16 | +183.8% | Aug 9, 2021 |
Track every rating change on ZTS the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationZoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology.…
Historical context
All ZTS earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| RDY Dr. Reddy's Laboratories Limited | FY2027 Q2 · Calendar Q4 2026 | +24.0% | -0.2% | Dr. Reddy’s: margins improve as semaglutide rollout advances |
| DGX Quest Diagnostics Incorporated | FY2026 Q3 · Calendar Q4 2026 | +4.5% | +1.8% | Quest Diagnostics: growth broadens, but PAMA remains a headwind |
| ARGX argenx SE | FY2026 Q3 · Calendar Q4 2026 | — | -1.6% | argenx: VYVGART momentum and a broader late-stage pipeline |
| MEDP Medpace Holdings, Inc. | FY2026 Q3 · Calendar Q4 2026 | +9.0% | -1.3% | Medpace: Record awards lift backlog as 2026 outlook improves |
| MOH Molina Healthcare, Inc. | FY2026 Q3 · Calendar Q4 2026 | +12.7% | +0.8% | Molina reaffirms 2026 outlook as Florida contract scales |
Latest beats and misses
Who reports nextBeat on EPS
- FCNCAFY2026 Q3 · October 23, 2026+19.9% EPS+8.2% move
- FCNCNFY2026 Q3 · October 23, 2026+19.9% EPS+0.2% move
- FCNCOFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- FCNCPFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- RDYFY2027 Q2 · October 23, 2026+24.0% EPS-0.2% move
- SLBFY2026 Q3 · October 23, 2026+3.7% EPS+7.1% move
Missed on EPS
- INFYFY2027 Q2 · October 23, 2026-4.8% EPS-6.6% move
- BBDFY2026 Q3 · October 22, 2026-7.7% EPS+3.0% move
- SNAFY2026 Q3 · October 22, 2026-5.9% EPS-3.4% move
- SPOTFY2026 Q3 · October 22, 2026-11.6% EPS+11.1% move
- VRSNFY2026 Q3 · October 22, 2026-2.0% EPS-0.9% move
- HBANMFY2026 Q3 · October 22, 2026-5.3% EPS+0.5% move
Get the ZTS recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-01-30T00:03:07.291072+00:00
- Polygon adjusted daily market bars · 2026-10-24T17:20:42.828996+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-24T17:20:42.826135+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-24. For educational purposes only; not investment advice.